1. Pink Sheet
  2. >>Geography
  3. >>Europe

Antimicrobial Exclusivity Vouchers ‘The Only Way To Go’

Many EU Countries, Generics Firms & Others Oppose The Voucher Idea

 
• By Ian Schofield

“If you don’t like it, come up with a better solution,” proponents of the transferable exclusivity voucher scheme said at a webinar on tackling antimicrobial resistance.

Idea breakthrough and the power to demolish an obstacle with creative thinking and innovative solutions as a light bulb shaped as a wrecking ball with 3D illustration elements. - Illustration
New ideas are needed to break the AMR barrier • Source: Shutterstock

The European Commission’s proposal to use transferable exclusivity vouchers as a way of encouraging companies to develop new antimicrobial drugs has drawn praise and criticism in equal measure.

For some, the idea is the best way to fix the “broken” antimicrobial business model, while others say it would...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent And Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.